Physician profile
Gregory J Smull
NPI 1093780520
$903.96
in general payments reported to CMS, 2019-2025
19 companies · $63.75 in 2025
The $63.75 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $169 · 2020: $263 · 2021: $154 · 2022: $104 · 2023: $110 · 2024: $39.87 · 2025: $63.75.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $214.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $213.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $248.75 | 2019-2025 | Nucala, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $138.92 | 2019-2023 | Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $66.68 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $58.06 | 2020-2021 | |
| Regeneron Healthcare Solutions, INC. | $50.69 | 2019-2022 | |
| Baxter Healthcare | $43.75 | 2022-2025 | Hillrom - Vest System Model 105 Home Care |
| Bayer Healthcare Pharmaceuticals INC. | $42.66 | 2019-2020 | |
| Amgen INC. | $30.18 | 2023 | Tezspire |
| Insmed, INC. | $28.27 | 2024 | Arikayce |
| Mylan Specialty L.P. | $24.88 | 2020 | |
| Csl Behring | $24.45 | 2020 | |
| Actelion Pharmaceuticals US, INC. | $24.11 | 2023 | Uptravi, Opsumit |
| Merck Sharp & Dohme LLC | $23.03 | 2023 | Zerbaxa, Dificid, Recarbrio |
| Ucb, INC. | $22.86 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $21.21 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $17.60 | 2020 | |
| Philips North America LLC | $14.61 | 2020 | |
| Vapotherm INC | $11.65 | 2022 | |
| Ambu INC. | $11.60 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Smull listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.